40
Participants
Start Date
May 31, 2012
Primary Completion Date
January 31, 2015
Study Completion Date
June 30, 2015
10 μg Na-GST-1/Alhydrogel
3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
30 μg Na-GST-1/Alhydrogel
3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
100 μg Na-GST-1/Alhydrogel
3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
3 doses 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
3 doses of 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
Children's National Medical Center, Washington D.C.
Collaborators (1)
Children's National Research Institute
OTHER
George Washington University
OTHER
Baylor College of Medicine
OTHER